Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00673556 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate
A Phase 3 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 195
- Enrollment target
NCT00673556 is a Phase 3 study that has completed, run by Astellas Pharma. The registered enrollment target is 195 participants.
The verdict
NCT00673556, a Phase 3 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 195 participants
- Enrollment target
Study Summary
To assess the efficacy and safety of Alefacept compared to placebo for the treatment of Chronic Plaque Psoriasis in patients for whom conventional therapies are ineffective and inappropriate
Interventions
- DRUG placebo
- DRUG alefacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 2003-10 |
| Est. Completion | 2005-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00673556
The ClinicalTrials.gov registry entry for NCT00673556 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 195 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00673556 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00673556 about?
NCT00673556 is a clinical study titled "A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate". To assess the efficacy and safety of Alefacept compared to placebo for the treatment of Chronic Plaque Psoriasis in patients for whom conventional therapies are ineffective and inappropriate
What is the current status of trial NCT00673556?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 195 participants. The study started on 2003-10. Estimated completion is 2005-05.
What interventions are being tested in trial NCT00673556?
The interventions under investigation include: placebo (DRUG), alefacept (DRUG).
Who is sponsoring clinical trial NCT00673556?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.